Exploring concepts of in vitro time-dependent CYP inhibition assays

Bibliography

• Grimm SW, Einolf HJ, Hall SD, et al. The conduct of in vitro studies to address time-dependent inhibition of drug-metabolizing enzymes: a perspective of the pharmaceutical research and manufacturers of America. Drug Metab Dispos 2009;37:1355-70
   PubMed Web of Science ®Google Scholar
• European Medicines Agency [2012] Guideline on the Investigation of Drug Interactions CPMP/EWP/560/95/Rev. 1
   Google Scholar
• USFDA. Guidance for Industry Drug Interaction Studies —Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations. DRAFT GUIDANCE 2012. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM292362.pdf [Last accessed 4 October 2013]
   Google Scholar
• Honig P, Wortham D, Zamani K, et al. Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. JAMA 1993;269:1513-18
   PubMed Web of Science ®Google Scholar
• Zimmerlin A, Trunzer M, Faller B. CYP3A time-dependent inhibition risk assessment validated with 400 reference drugs. Drug Metab Dispos 2011;39:1039-46
   PubMed Web of Science ®Google Scholar
• Orr STM, Ripp SL, Ballard TE, et al. Mechanism-based inactivation [MBI] of cytochrome P450 enzymes: structure–activity relationships and discovery strategies to mitigate drug–drug interaction risks. J Med Chem 2012;55:4896-933
   PubMed Web of Science ®Google Scholar
• Ghanbari F, Rowland-Yeo K, Bloomer JC, et al. A critical evaluation of the experimental design of studies of mechanism based enzyme inhibition, with implications for in vitro-in vivo extrapolation. Curr Drug Metab 2006;7:315-34
   PubMed Web of Science ®Google Scholar
• Kalgutkar AS, Obach RS, Maurer TS. Mechanism-based inactivation of cytochrome P450 enzymes: chemical mechanisms, structure-activity relationships and relationship to clinical drug-drug interactions and idiosyncratic adverse drug reactions. Curr Drug Metab 2007;8:407-47
   PubMed Web of Science ®Google Scholar
• Riley RJ, Grime K, Weaver R. Time-dependent CYP inhibition. Expert Opin Drug Metab Toxicol 2007;3:51-66
   PubMed Web of Science ®Google Scholar
• Ma B, Prueksaritanont T, Lin JH. Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos 2000;28:125-30
   PubMed Web of Science ®Google Scholar
• Bertelsen KM, Venkatakrishnan K, Von Moltke LL, et al. Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine. Drug Metab Dispos 2003;31:289-93
   PubMed Web of Science ®Google Scholar
• Obach RS, Walsky RL, Venkatakrishnan K. Mechanism-based inactivation of human cytochrome P450 enzymes and the prediction of drug-drug interactions. Drug Metab Dispos 2007;35:246-55
   PubMed Web of Science ®Google Scholar
• Parkinson A, Kazmi F, Buckley DB, et al. An evaluation of the dilution method for identifying metabolism-dependent inhibitors of cytochrome P450 enzymes. Drug Metab Dispos 2011;39:1370-87
   PubMed Web of Science ®Google Scholar
• Perloff ES, Mason AK, Dehal SS, et al. Validation of a cytochrome P450 time dependent inhibition assay: a two time point IC50 shift approach facilitates kinact assay design. Xenobiotica 2009;39:99-112
   PubMed Web of Science ®Google Scholar
• Mukadam S, Tay S, Tran D, et al. Evaluation of time-dependent cytochrome p450 inhibition in a high-throughput, automated assay: introducing a novel area under the curve shift approach. Drug Metab Lett 2012;6:43-53
   PubMedGoogle Scholar
• Foti RS, Fisher MB. Impact of incubation conditions on bufuralol human clearance predictions: enzyme lability and non-specific binding. Drug Metab Dispos 2004;32:295-304
   PubMed Web of Science ®Google Scholar
• Burt HJ, Pertinez H, Säll C, et al. A progress curve approach for assessing time-dependent inhibition of CYP3A4. Drug Metab Dispos 2012;40:1658-67
   PubMed Web of Science ®Google Scholar
• Berry LM, Zhao Z, Lin MJ. Dynamic modeling of cytochrome P450 inhibition in vitro: impact of inhibitor depletion on IC50-shift. Drug Metab Dispos 2013;41(7):1433-41
   PubMed Web of Science ®Google Scholar
• Li P, Lu C, Balani SK, et al. A refined cytochrome P450 IC50 shift assay for reliably identifying CYP3A time-dependent inhibitors. Drug Metab Dispos 2011;39:1054-7
   PubMed Web of Science ®Google Scholar
• Atkinson A, Kenny JR, Grime K. Automated assessment of time-dependent inhibition of human cytochrome P450 enzymes using liquid chromatography-tandem mass spectrometry analysis. Drug Metab Dispos 2005;33:1637-47
   PubMed Web of Science ®Google Scholar
• Grime KH, Bird J, Ferguson D, Riley RJ. Mechanism-based inhibition of cytochrome P450 enzymes: an evaluation of early decision making in vitro approaches and drug–drug interaction prediction methods. Eur J Pharm Sci 2009;36:175-1
   PubMed Web of Science ®Google Scholar
• Henne KR, Thuy BT, VandenBrink BM, et al. Sequential metabolism of AMG 487, a novel CXCR3 antagonist, results in formation of quinone reactive metabolites that covalently modify CYP3A4 Cys239 and cause time-dependent inhibition of the enzyme. Drug Metab Dispos 2012;40:1429-40
   PubMed Web of Science ®Google Scholar
• Tonn GR, Wong SG, Wong SC, et al. An inhibitory metabolite leads to dose- and time-dependent pharmacokinetics of [R]-N-{1-[3-[4-ethoxy-phenyl]-4-oxo-3,4-dihydro-pyrido[2,3-d]pyrimidin-2-y l]-ethyl}-N-pyridin-3-yl-methyl-2-[4-trifluoromethoxy-phenyl]-acetamide [AMG 487] in human subjects after multiple dosing. Drug Metab Dispos 2009;37:502-13
   PubMed Web of Science ®Google Scholar
• Wang YH, Jones DR, Hall SD. Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos 2004;32:259-66
   PubMed Web of Science ®Google Scholar
• Hanson KL, VandenBrink BM, Babu KN, et al. Sequential metabolism of secondary alkyl amines to metabolic-intermediate complexes: opposing roles for the secondary hydroxylamine and primary amine metabolites of desipramine, [s]-fluoxetine, and N-desmethyldiltiazem. Drug Metab Dispos 2010;38:963-72
   PubMed Web of Science ®Google Scholar
• VandenBrink BM, Isoherranen N. The role of metabolites in predicting drug-drug interactions: focus on irreversible cytochrome P450 inhibition. Curr Opin Drug Discov Devel 2010;13:66-77
   PubMed Web of Science ®Google Scholar
• Yates P, Eng H, Di L, et al. Statistical methods for analysis of time-dependent inhibition of cytochrome P450 enzymes. Drug Metab Dispos 2012;40:2289-96
   PubMed Web of Science ®Google Scholar
• Fairman DA, Collins C, Chapple S. Progress curve analysis of CYP1A2 inhibition: a more informative approach to the assessment of mechanism-based inactivation? Drug Metab Dispos 2007;35:2159-65
   PubMed Web of Science ®Google Scholar
• Salminen KA, Leppänen J, Venäläinen JI, et al. Simple, direct, and informative method for the assessment of CYP2C19 enzyme inactivation kinetics. Drug Metab Dispos 2011;39:412-18
   PubMed Web of Science ®Google Scholar
• Knight GC, Waley SG. Inhibition of class C beta-lactamases by [1′R,6R]-6-[1′-hydroxy]benzylpenicillanic acid SS-dioxide. Biochem J 1985;225:435-9
   PubMed Web of Science ®Google Scholar
• Waley SG. Kinetics of suicide substrates. Practical procedures for determining parameters. Biochem J 1985;227:843-9
   PubMed Web of Science ®Google Scholar
• Zhou ZW, Zhou SF. Application of mechanism-based CYP inhibition for predicting drug-drug interactions. Expert Op Drug Metab Toxicol 2009;5:579-605
   PubMed Web of Science ®Google Scholar
• Ito K, Ogihara K, Kanamitsu S, et al. Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes. Drug Metab Dispos 2003;31:945-54
   PubMed Web of Science ®Google Scholar
• Zientek M, Stoner C, Ayscue R, et al. Integrated in silico-in vitro strategy for addressing cytochrome P450 3A4 time-dependent inhibition. Chem Res Toxicol 2010;23:664-76
   PubMed Web of Science ®Google Scholar
• Mayhew BS, Jones DR, Hall SD. An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation. Drug Metab Dispos 2000;28:1031-7
   PubMed Web of Science ®Google Scholar
• Ito K, Iwatsubo T, Kanamitsu S, et al. Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport. Annu Rev Pharmacol Toxicol 1998;38:461-99
   PubMed Web of Science ®Google Scholar
• Houston JB, Galetin A. Methods for predicting in vivo pharmacokinetics using data from in vitro assays. Curr Drug Metab 2008;9:940-51
   PubMed Web of Science ®Google Scholar
• McGinnity DF, Berry AJ, Kenny JR, et al. Evaluation of time-dependent cytochrome P450 inhibition using cultured human hepatocytes. Drug Metab. Dispos 2006;34:1291-300
   PubMed Web of Science ®Google Scholar
• Kenny JR, Mukadam S, Zhang C, et al. Drug-drug interaction potential of marketed oncology drugs: in vitro assessment of time-dependent cytochrome P450 inhibition, reactive metabolite formation and drug-drug interaction prediction. Pharm Res 2012;29:1960-76
   PubMed Web of Science ®Google Scholar
• Sekiguchi N, Higashida A, Kato M, et al. Prediction of drug-drug interactions based on time-dependent inhibition from high throughput screening of cytochrome P450 3A4 inhibition. Drug Metab Pharmacokinet 2009;24:500-10
   PubMed Web of Science ®Google Scholar
• Zhou S, Yung Chan S, Cher Goh B, et al. Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet 2005;44:279-304
   PubMed Web of Science ®Google Scholar
• Kenny JR, Grime K. Pharmacokinetic consequences of time-dependent inhibition using the isolated perfused rat liver model. Xenobiotica 2006;36:351-65
   PubMed Web of Science ®Google Scholar
• Zhou SF. Potential strategies for minimizing mechanism-based inhibition of cytochrome P450 3A4. Curr.Pharm.Des 2008;14:990-1000
   PubMed Web of Science ®Google Scholar
• Vieira MLT, Kirby B, Ragueneau-Majlessi I, et al. Evaluation of Various Static In vitro-In vivo Extrapolation Models for Risk Assessment of CYP3A Inhibition Potential of an Investigational Drug. Clin Pharmacol Ther 2013; doi: 10.1038/clpt.2013.187; Epub ahead of print
   PubMed Web of Science ®Google Scholar
• Venkatakrishnan K, Obach RS. Drug–drug interactions via mechanism-based cytochrome P450 inactivation: points to consider for risk assessment from in vitro data and clinical pharmacologic evaluation. Curr Drug Metab 2007;8:449-62
   PubMed Web of Science ®Google Scholar
• Soars MG, McGinnity DF, et al. The pivotal role of hepatocytes in drug discovery. Chem Biol Interact 2007;168:2-15
   PubMed Web of Science ®Google Scholar
• Zhao P, Kunze KL, Lee CA. Evaluation of time-dependent inactivation of CYP3A in cryopreserved human hepatocytes. Drug Metab Dispos 2005;33:853-61
   PubMed Web of Science ®Google Scholar
• Lu C, Berg C, Prakash SR, et al. Prediction of pharmacokinetic drug-drug interactions using human hepatocyte suspension in plasma and cytochrome P450 phenotypic data. III. In vitro-in vivo correlation with fluconazole. Drug Metab Dispos 2008;36:1261-6
   Google Scholar
• Xu L, Chen Y, Pan Y, et al. Prediction of human drug-drug interactions from time-dependent inactivation of CYP3A4 in primary hepatocytes using a population-based simulator. Drug Metab Dispos 2009;37:2330-9
   Google Scholar
• Chen Y, Liu L, Monshouwer M, Fretland AJ. Determination of time-dependent inactivation of CYP3A4 in cryopreserved human hepatocytes and assessment of human drug-drug interactions. Drug Metab Dispos 2011;39:2085-92
   Google Scholar
• Mao J, Mohutsky MA, Harrelson JP, et al. Prediction of CYP3A-mediated drug-drug interactions using human hepatocytes suspended in human plasma. Drug Metab Dispos 2011;39:591-602
   Google Scholar
• Albaugh DR, Fullenwider CL, Fisher MB, Hutzler JM. Time-dependent inhibition and estimation of CYP3A clinical pharmacokinetic drug-drug interactions using plated human cell systems. Drug Metab Dispos 2012;40:336-44
   Google Scholar
• Zhang JG, Stresser DM, Yan Z, Caldwell G. Evaluation of time-dependent inhibition of CYP3A4 in human hepatocytes in “optimization in drug discovery: in-vitro ADME assays”. editors. Humana Press; 2013
   Google Scholar
• Wang Y-H. Confidence assessment of the Simcyp time-based approach and static mathematical model in predicting clinical drug-drug interactions for mechanism-based CYP3A inhibitors. Drug Metab Dispos 2010;38:1094-104
   PubMed Web of Science ®Google Scholar
• Mao J, Mohutsky MA, Harrelson JP, et al. Predictions of cytochrome P450-mediated drug-drug interactions using cryopreserved human hepatocytes: comparison of plasma and protein-free media incubation conditions. Drug Metab Dispos 2012;40:706-16
   PubMed Web of Science ®Google Scholar
• Mao J, Johnson TR, Shen Z, Yamazaki S. Prediction of crizotinib-midazolam interaction using the Simcyp population-based simulator: comparison of CYP3A time-dependent inhibition between human liver microsomes versus hepatocytes. Drug Metab Dispos 2013;41:343-52
   PubMed Web of Science ®Google Scholar
• Honkalammi J, Niemi M, Neuvonen PJ, Backman JT. Dose-dependent interaction between gemfibrozil and repaglinide in humans: strong inhibition of CYP2C8 with subtherapeutic gemfibrozil doses. Drug Metab Dispos 2011;39:1977-86
   PubMed Web of Science ®Google Scholar
• Reese MJ, Wurm RM, Muir KT, et al. An in vitro mechanistic study to elucidate the desipramine/bupropion clinical drug-drug interaction. Drug Metab Dispos 2008;36:1198-201
   PubMed Web of Science ®Google Scholar
• Ogilvie BW, D, Zhang et al. Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions. Drug Metab Dispos 2006;34:191-7
   PubMed Web of Science ®Google Scholar
• Kirby BJ, Collier AC, Kharasch ED, et al. Complex drug interactions of HIV protease inhibitors 2: in vivo induction and in vitro to in vivo correlation of induction of cytochrome P450 1A2, 2B6, and 2C9 by ritonavir or nelfinavir. Drug Metab Dispos 2011;39:2329-37
   PubMed Web of Science ®Google Scholar
• Berry LM, Zhao Z. An examination of IC50 and IC50-shift experiments in assessing time-dependent inhibition of CYP3A4, CYP2D6 and CYP2C9 in human liver microsomes. Drug Metab Lett 2008;21:51-9
   Google Scholar
• Stresser DM, Mason AK, Dehal SS, et al. The length of preincubation times in abbreviated cytochrome P450 time-dependent inhibition studies: one size fits all? [abstract 150]. Proceeding of 17th N. Am. ISSX meeting; 2011
   Google Scholar
• Parkinson A, Kazmi F, Buckley DB, et al. System-dependent outcomes during the evaluation of drug candidates as inhibitors of cytochrome P450 [CYP] and uridine diphosphate glucuronosyltransferase [UGT] enzymes: human hepatocytes versus liver microsomes versus recombinant enzymes. Drug Metab Pharmacokinet 2010;25:16-27
   PubMed Web of Science ®Google Scholar
• Ito K, Brown HS, Houston JB. Database analyses for the prediction of in vivo drug-drug interactions from in vitro data. Br J Clin Pharmacol 2004;57:473-86
   PubMed Web of Science ®Google Scholar